The BZW2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from Jurkat E6.1 cells, featuring targeted disruption of the BZW2 gene. This loss-of-function model provides a heterogeneous knockout pool, avoiding clonal selection artifacts while better reflecting cellular heterogeneity found in disease contexts. The product offers a robust system to study BZW2-dependent phenotypes in a T-lymphocyte background, enabling population-level analyses that are highly relevant to translational research and drug development.
The Jurkat E6.1 host cell line is a well-characterized human T-cell leukemia line that retains functional TCR/CD3 signaling. It is commonly used to dissect proximal T-cell activation, IL-2 production, and apoptosis regulation. Its leukemic origin makes it a pertinent model for investigating molecular mechanisms of T-cell malignancies and drug resistance. The cell line’s defined signaling pathways facilitate the study of genes involved in stress responses and translational control within the context of lymphoid neoplasms.
BZW2 encodes an eIF5-mimic protein that regulates cap-dependent translation by modulating eIF2?? phosphorylation. Under stress, upstream kinases GCN2 and PERK phosphorylate eIF2??, inhibiting global protein synthesis while inducing ATF4 and CHOP. BZW2 counteracts this by interacting with the eIF2 complex, eIF3 complex, GCN2, and the 40S ribosomal subunit to prevent eIF2?? phosphorylation, thereby sustaining translation. The protein also functionally interfaces with the mTOR pathway through components such as mTORC1, S6K1, and 4E-BP1. Knockout of BZW2 disrupts this regulatory balance, leading to elevated eIF2?? phosphorylation, ATF4/CHOP induction, and impaired stress adaptation.
In Jurkat T cells, BZW2 supports proliferation and survival; its loss is predicted to compromise stress handling, potentially altering TCR signaling, IL-2 output, and apoptotic thresholds. This makes the knockout particularly valuable for studying acute lymphoblastic leukemia and T-cell malignancies, where translational dysregulation drives oncogenesis and chemoresistance. The model allows dissection of how translational control influences leukemic cell fate and drug sensitivity.
Research applications include T-cell leukemia biology, apoptosis signaling, drug resistance mechanisms, proliferation assays, and translational control studies. Compatible techniques encompass Western blotting for p-eIF2??, ATF4, and CHOP; RT-qPCR; flow cytometry for Annexin V and cell cycle; MTT assay; polysome profiling; and RNA-seq. The polyclonal nature supports pooled screening approaches. For further details, contact Ascent Research.
